Evidence map›Paper›PMID 30381327›Full record

ArticleMolecular & cellular proteomics : MCP2019

Identification of a Specific Translational Machinery via TCTP-EF1A2 Interaction Regulating NF1-associated Tumor Growth by Affinity Purification and Data-independent Mass Spectrometry Acquisition (AP-DIA).

Daiki Kobayashi, Takaho Tokuda, Kyosuke Sato, Hiroki Okanishi, Megumi Nagayama, Mio Hirayama-Kurogi, Sumio Ohtsuki, Norie Araki

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Cells · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Daiki KobayashiDepartment of Tumor Genetics and Biology, Graduate School of Medical Sciences, Faculty of Life Sciences.
Takaho TokudaDepartment of Tumor Genetics and Biology, Graduate School of Medical Sciences, Faculty of Life Sciences.
Kyosuke SatoDepartment of Molecular Physiology, Faculty of Life Sciences.
Hiroki OkanishiDepartment of Tumor Genetics and Biology, Graduate School of Medical Sciences, Faculty of Life Sciences.
Megumi NagayamaDepartment of Tumor Genetics and Biology, Graduate School of Medical Sciences, Faculty of Life Sciences.
Mio Hirayama-KurogiDepartment of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University.
Sumio OhtsukiDepartment of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University.
Norie ArakiDepartment of Tumor Genetics and Biology, Graduate School of Medical Sciences, Faculty of Life Sciences,. Electronic address: nori@gpo.kumamoto-u.ac.jp.
Cancer Genetics (United States) · USKumamoto University · JPLife University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant disease that predisposes individuals to developing benign neurofibromas and malignant peripheral nerve sheath tumors (MPNST). The mechanism of NF1-tumorigenesis or the curatives have not been established. Using unique trascriptome and proteome integration method, iPEACH (1), we previously identified translationally controlled tumor protein (TCTP) as a novel biological target for NF1-associated tumors (2). Here, we identified specific TCTP-interacting proteins by sequential affinity purification and data-independent mass spectrometry acquisition (AP-DIA/SWATH) to investigate the role of TCTP in NF1-associated malignant tumors. TCTP mainly interacts with proteins related to protein synthesis and especially to elongation factor complex components, including EF1A2, EF1B, EF1D, EF1G, and valyl-tRNA synthetase (VARS), in NF1-deficient malignant tumor cells. Interestingly, TCTP preferentially binds to EF1A2 (normally found only in neural and skeletal-muscle cells and several cancer cells), rather than EF1A1 despite the high homologies (98%) in their sequences. The docking simulation and further validations to study the interaction between TCTP and EF1A2 revealed that TCTP directly binds with EF1A2 via the contact areas of EF1A2 dimerization. Using unique and common sequences between EF1A2 and EF1A1 in AP-DIA/SWATH, we quantitatively validated the interaction of EF1A2 and TCTP/other elongation factors and found that TCTP coordinates the translational machinery of elongation factors via the association with EF1A2. These data suggest that TCTP activates EF1A2-dependent translation by mediating complex formation with other elongation factors. Inhibiting the TCTP-EF1A2 interaction with EF1A2 siRNAs or a TCTP inhibitor, artesunate, significantly down-regulated the factors related to protein translation and caused dramatic suppression of growth/translation in NF1-associated tumors. Our findings demonstrate that a specific protein translation machinery related to the TCTP-EF1A2 interaction is functionally implicated in the tumorigenesis and progression of NF1-associated tumors and could represent a therapeutic target.

Indexed as

Binding SitesBiomarkers, TumorCell Line, TumorChromatography, AffinityGene Expression ProfilingHeLa CellsHumansMass SpectrometryModels, MolecularMolecular Docking SimulationNeurofibromatosis 1Neurofibromin 1NeurofibrosarcomaPeptide Chain Elongation, TranslationalPeptide Elongation Factor 1Protein BindingBiomarkers, TumorEEF1A2 protein, humanNeurofibromin 1NF1 protein, humanPeptide Elongation Factor 1TPT1 protein, humanTumor Protein, Translationally-Controlled 1Affinity ProteomicsCancer BiologyEF1A2Neurofibromatosis Type-1 (NF1)NF1 Malignant TumorProtein-Protein InteractionsProtein Translation ElongationSWATH-MSTCTPTranslation

Identifiers

PMID30381327
PMCPMC6356078
OpenAlexW2898805956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.